KR20110111420A - 암을 위한 예방/치료제 - Google Patents

암을 위한 예방/치료제 Download PDF

Info

Publication number
KR20110111420A
KR20110111420A KR1020117017317A KR20117017317A KR20110111420A KR 20110111420 A KR20110111420 A KR 20110111420A KR 1020117017317 A KR1020117017317 A KR 1020117017317A KR 20117017317 A KR20117017317 A KR 20117017317A KR 20110111420 A KR20110111420 A KR 20110111420A
Authority
KR
South Korea
Prior art keywords
group
arg
optionally substituted
asn
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117017317A
Other languages
English (en)
Korean (ko)
Inventor
히사노리 마츠이
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42025816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20110111420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20110111420A publication Critical patent/KR20110111420A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020117017317A 2008-12-29 2009-12-28 암을 위한 예방/치료제 Withdrawn KR20110111420A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20388708P 2008-12-29 2008-12-29
US61/203,887 2008-12-29

Publications (1)

Publication Number Publication Date
KR20110111420A true KR20110111420A (ko) 2011-10-11

Family

ID=42025816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117017317A Withdrawn KR20110111420A (ko) 2008-12-29 2009-12-28 암을 위한 예방/치료제

Country Status (26)

Country Link
US (1) US20110312898A1 (https=)
EP (1) EP2379053A1 (https=)
JP (1) JP2012513982A (https=)
KR (1) KR20110111420A (https=)
CN (1) CN102333520B (https=)
AR (1) AR074918A1 (https=)
AU (1) AU2009334235A1 (https=)
BR (1) BRPI0923663A2 (https=)
CA (1) CA2748517A1 (https=)
CL (1) CL2011001519A1 (https=)
CO (1) CO6382105A2 (https=)
CR (1) CR20110374A (https=)
DO (1) DOP2011000163A (https=)
EA (1) EA019738B1 (https=)
EC (1) ECSP11011166A (https=)
GE (1) GEP20146001B (https=)
IL (1) IL212913A0 (https=)
MA (1) MA32935B1 (https=)
MX (1) MX2011006170A (https=)
NZ (1) NZ593381A (https=)
PE (1) PE20110939A1 (https=)
TN (1) TN2011000250A1 (https=)
TW (1) TW201029660A (https=)
UY (1) UY32367A (https=)
WO (1) WO2010076896A1 (https=)
ZA (1) ZA201103627B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592379B2 (en) * 2008-04-30 2013-11-26 Kyoto University Metastin derivative and use thereof
KR20120098906A (ko) * 2009-12-22 2012-09-05 다케다 야쿠힌 고교 가부시키가이샤 서방성 제제
BR112012032544A2 (pt) * 2010-06-25 2016-10-11 Takeda Pharmaceutical formulação de liberação prolongada, uso de um composto, e, método para produzir a formulação de liberação prolongada.
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
WO2016099232A2 (ru) * 2014-10-20 2016-06-23 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтический состав лечебно-профилактического действия и способ его приготовления
MA46353A (fr) 2016-09-30 2019-08-07 Myovant Sciences Gmbh Méthodes de traitement de l'infertilité féminine
WO2024206577A1 (en) * 2023-03-28 2024-10-03 Radionetics Oncology, Inc. Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof
US12521455B2 (en) 2024-04-08 2026-01-13 Radionetics Oncology, Inc. Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
CN1972959A (zh) * 2004-06-25 2007-05-30 武田药品工业株式会社 转移素衍生物及其用途
AR049938A1 (es) * 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途

Also Published As

Publication number Publication date
US20110312898A1 (en) 2011-12-22
ECSP11011166A (es) 2011-07-29
MX2011006170A (es) 2011-06-27
UY32367A (es) 2010-07-30
AR074918A1 (es) 2011-02-23
TN2011000250A1 (en) 2012-12-17
TW201029660A (en) 2010-08-16
EP2379053A1 (en) 2011-10-26
MA32935B1 (fr) 2012-01-02
CN102333520A (zh) 2012-01-25
EA019738B1 (ru) 2014-05-30
ZA201103627B (en) 2012-09-26
GEP20146001B (en) 2014-01-10
DOP2011000163A (es) 2011-07-31
PE20110939A1 (es) 2012-01-19
CO6382105A2 (es) 2012-02-15
CR20110374A (es) 2011-09-19
EA201100882A1 (ru) 2011-12-30
IL212913A0 (en) 2011-07-31
NZ593381A (en) 2013-01-25
WO2010076896A1 (en) 2010-07-08
BRPI0923663A2 (pt) 2016-01-19
CN102333520B (zh) 2013-11-06
AU2009334235A1 (en) 2010-07-08
JP2012513982A (ja) 2012-06-21
CA2748517A1 (en) 2010-07-08
CL2011001519A1 (es) 2012-03-16

Similar Documents

Publication Publication Date Title
JP5686825B2 (ja) メタスチン誘導体およびその用途
JP4654284B2 (ja) メタスチン誘導体およびその用途
JP5298087B2 (ja) メタスチン誘導体およびその用途
KR20110111420A (ko) 암을 위한 예방/치료제
US8404643B2 (en) Metastin derivatives and use thereof
US20110118172A1 (en) Metastin derivative and use thereof
JP4804714B2 (ja) メタスチン誘導体およびその用途
RU2454425C2 (ru) Производные метастина и их применение
CN1972959A (zh) 转移素衍生物及其用途
KR20070031949A (ko) 메타스틴 유도체 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000